Given the versatility of VX-770 in treating multiple CFTR class defects35,36 as well as non-CF lung diseases resulting from acquired CFTR dysfunction37–39, we expect that the additional classification of VX-445 as a CFTR potentiator will have broad impact in the treatment of CF and non-CF lung disease. The gene discussed is CFTR; the disease is cystic fibrosis.